source
- Mirum's Phase 3 Trial Shows Brelovitug Achieves Primary Endpoint in Hepatitis D StudyMirum Pharmaceuticals reported that its phase 3 Azure-1 trial in chronic hepatitis delta met its primary efficacy goal, marking a significant step toward market entry in a field dominated by Gilead…
- Kodiak Sciences' eye disease drug matches Eylea in Phase 3, sending stock soaringKodiak Sciences reported that two of its eye‑disease candidates performed on par with aflibercept (Eylea) in a pivotal Phase 3 trial. The data suggest comparable efficacy in treating the targeted r…